High intraindividual week-to-week variability in BASDAI and BASFI values: Are several evaluations needed before starting or stopping TNFα antagonist therapy for spondyloarthropathies? - 19/04/08
, Lætitia Tortellier, Delphine Lavy-Bregeon, Benoît Le Goff, Yves Maugars
Corresponding author. Service de Rhumatologie, Hôtel-Dieu – CHU Nantes, 1, Place Alexis, 44093 Nantes Cedex 01, France. Tel.: +33 02 4008 4822/25/01; fax: +33 02 4008 4830.Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 5 |
| Iconografia | 4 |
| Video | 0 |
| Altro | 0 |
Abstract |
Objective |
To evaluate intraindividual variability of the BASDAI, BASFI, and HAQ in patients with spondyloarthropathies.
Methods |
The three variables were collected prospectively in 24 patients, once a week for 30weeks. They were also collected retrospectively in 31 patients on stable infliximab regimens with a mean of 11.5±4 injections, starting at the fourth infusion.
Results |
The BASDAI and BASFI showed high intraindividual variability from week to week; SDs greater than 1 were found for the BASDAI in 14/24 patients and for the BASFI in 10/24 patients, and ranges greater than 4/10 occurred for the BASDAI in 13/24 patients and for the BASFI in 10/24 patients. Although the mean BASDAI was greater than 4 in only 6/24 patients, values greater than 4 occurred on one or more occasions in 19 (79%) patients. The retrospective study of infliximab-treated patients from the fourth infusion onward also showed high variability of BASDAI and BASFI values, with SDs greater than 1 in 18/31 patients and ranges greater than 4 in 14/31 patients and greater than 2 in 22/31 patients.
Conclusion |
Repeated determination of the BASDAI and BASFI by the patients (using paper forms or personal digital assessments) may help to identify candidates for treatment intensification, to optimize infliximab injection regimens in good responders, and to avoid unnecessary switching from one TNF
antagonist to another.
Keywords : BASDAI, BASFI, Fluctuation, Variation, Monitoring, Anti-TNF, Spondyloarthropathy, Spondylarthritis, Ankylosing spondylitis
Mappa
Vol 75 - N° 2
P. 167-171 - marzo 2008 Ritorno al numero
Articolo precedente
- Long-term outcome of total knee replacement in patients with rheumatoid arthritis
- Klemmens Trieb, Maximillian Schmid, Thomas Stulnig, Wolfgang Huber, Axel Wanivenhaus
- Distribution of HLA-B*27 subtypes in Tunisians and their association with ankylosing spondylitis
- Karima Ben Radhia, Saloua Ayed-Jendoubi, Imene Sfar, Thouraya Ben Romdhane, Mouna Makhlouf, Yousr Gorgi, Khaled Ayed
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?